Return to Home

Zentalis Pharmaceuticals, Inc.

ZNTL

Find Out if You Qualify for a Financial Reward by filling out the form below.

Zentalis Pharmaceuticals, Inc. Form












Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Zentalis announced on June 18, 2024, that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).”

Following this news, Zentalis’s stock price fell over 50% on June 18, 2024.

Find More Cases

Ticker Symbol Company Name Join Deadline
NFE New Fortress Energy Inc. November 18, 2024 Join
MGX Metagenomi, Inc. November 25, 2024 Join
BMBL Bumble Inc. November 25, 2024 Join
UPS United Parcel Service, Inc. December 09, 2024 Join
EW Edwards Lifesciences Corporation December 13, 2024 Join
TD The Toronto-Dominion Bank December 23, 2024 Join